ArticleBMC public health2025
Impact of an optimized care model for advanced HIV disease: a non-randomized cluster study in Malawi.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite significant advances in HIV diagnosis and access to ART, many patients still present with advanced HIV disease (AHD). We assessed the effect of an optimized AHD care package on the screening and diagnosis of opportunistic diseases among clients enrolled in AHD care.
methodsThis non-randomized cluster design was conducted using a hub-and-spoke model. Twenty-two health facilities, including hub facilities (eight hub sites) and their associated spoke facilities (14 spoke sites), were purposively selected as intervention sites (IS) across three districts in Malawi. The optimized AHD package implemented in these IS included enhanced CD4 testing, tuberculosis (TB) and cryptococcal antigen (CrAg) screening, and appropriate treatment of opportunistic diseases delivered through a hub-and-spoke model. Thirteen non-intervention sites (NIS) (five hub and eight spoke sites) were chosen from four districts that did not implement the intervention and were matched with the IS based on rural/urban settings and health facility types. We abstracted individual-level data from routine clinical records of clients meeting the World Health Organization's definition of AHD between June and December 2021.
resultsOf 963 patients with AHD, 57.4% were seen at IS, and 42.6% at NIS. The IS showed higher proportions of AHD clients identified at (44.3% vs. 36.8%, p = 0.020) and increased screening of children under five years old (7.1% vs. 2.7%, p = 0.004). Additionally, IS diagnosed more cases of WHO stage 3 or 4 disease (47.6% vs. 40.5%, P = 0.029). Patients seen at IS were significantly more likely to receive TB symptom screening (Adjusted Relative Risk [ARR]: 1.13, 95% Confidence Interval [CI]: 1.06-1.21), urine lateral flow lipoarabinomannan test administration (ARR: 1.94, 95% CI: 1.18-3.20), and TB diagnosis (ARR: 2.64, 95% CI: 1.47-4.75). Screening for neurological signs in IS was also improved (ARR: 1.07, 95% CI: 1.02-1.13), as was the diagnosis of cryptococcal meningitis (ARR: 4.28, 95% CI: 1.58-11.70), compared to NIS. There was no difference in retention and mortality in the care of patients after twelve months of follow-up between IS and NIS.
conclusionOur study underscores the vital role of improving screening and diagnostic efforts for advanced HIV disease (AHD), notably targeting AHD-related opportunistic infections, including TB and Cryptococcal diseases. Word count: 4,832 words, excluding references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.